SCHEMBL17304136

SCHEMBL17304136

CC(C)Sc1nn(C)cc1[N+](=O)[O-]

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
ALDH1A1 P00352 3/20 0.41
POLB P06746 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 4/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
MITF O75030 1/20 0.35
NPC1 O15118 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NPY1R P25929 1/20 0.32
NPY2R P49146 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18418878 0.80 MAPT (0.44) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL18426690 0.73 L3MBTL1 (0.43) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL18426688 0.73 L3MBTL1 (0.43) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL2624375 0.73 MAPT (0.44) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL2760410 0.70 MAPT (0.47) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL12335522 0.70 ALDH1A1 (0.47) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL8920036 0.70 MAPT (0.47) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL30137920 0.70 MAPT (0.51) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL24792528 0.69 ALDH1A1 (0.41) MAPTALDH1A1POLBL3MBTL1LMNA
SCHEMBL16698871 0.68 MAPT (0.46) MAPTALDH1A1POLBL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3150592-B1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO LTD (CN) 2023-08-30 EP disclosed
CN-107540666-B Benzofuran pyrazole amine protein kinase inhibitor 杭州雷索药业有限公司 2023-03-24 CN disclosed
US-10710993-B2 Benzofuran pyrazole amine kinase inhibitor Hangzhou REX Pharmaceutical Co., LTD. (CN) 2020-07-14 US disclosed
US-20190225600-A1 BENZOFURAN PYRAZOLE AMINE KINASE INHIBITOR Hangzhou REX Pharmaceutical Co., LTD. (CN) 2019-07-25 US disclosed
EP-3476848-A1 BENZOFURAN PYRAZOLE AMINE PROTEIN KINASE INHIBITOR Hangzhou Rex Pharmaceutical Co., Ltd (CN) 2019-05-01 EP disclosed
US-10023593-B2 ALK kinase inhibitor, and preparation method and uses thereof BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) 2018-07-17 US disclosed
US-10023593-B2 ALK kinase inhibitor, and preparation method and uses thereof BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) 2018-07-17 US disclosed
US-10023593-B2 ALK kinase inhibitor, and preparation method and uses thereof BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) 2018-07-17 US disclosed
US-20170247392-A1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) 2017-08-31 US disclosed
US-20170247392-A1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) 2017-08-31 US disclosed
US-20170247392-A1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) 2017-08-31 US disclosed
EP-3150592-A1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF Beijing Pearl Biotechnology Limited Liability Company (CN) 2017-04-05 EP disclosed
EP-3150592-A1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF Beijing Pearl Biotechnology Limited Liability Company (CN) 2017-04-05 EP disclosed
WO-2015180685-A1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF 北京浦润奥生物科技有限责任公司 2015-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170247392-A1 ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF ALK, BRAF, ABL1 MAPT 2610/4885ALDH1A1 679/4885POLB 2723/4885
US-10023593-B2 ALK kinase inhibitor, and preparation method and uses thereof ALK, BRAF, ABL1 MAPT 2610/4885ALDH1A1 679/4885POLB 2723/4885
US-10710993-B2 Benzofuran pyrazole amine kinase inhibitor ALK, MAP3K5, ARAF MAPT 2121/4885ALDH1A1 1248/4885POLB 4082/4885
US-20190225600-A1 BENZOFURAN PYRAZOLE AMINE KINASE INHIBITOR ALK, MAP3K5, ARAF MAPT 2121/4885ALDH1A1 1248/4885POLB 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.